Tirzepatide and the 10‐year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three‐year <scp>SURMOUNT</scp> ‐1 trial
Tirzepatide treatment was associated with a reduction in the 10-year predicted risk of both cardiovascular outcomes and T2D in people with obesity and prediabetes.
Authors
- Georgios K. Dimitriadis (ORCID: https://orcid.org/0000-0002-6662-804X)
- Clare J. Lee (ORCID: https://orcid.org/0000-0002-0824-0207)
- Emily R. Hankosky (ORCID: https://orcid.org/0000-0001-9934-584X)
- Jérémie Lebrec
- Irina Jouravskaya
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
- W. Timothy Garvey
Institutions
- Eli Lilly (United States) (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1111/dom.70143
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Eli Lilly and Company